Ehsan Sadri, M.D., CEO and founder of Visionary Eye Institute, joins the Eye on Innovation podcast to discuss the advancements of interventional glaucoma. With host Carey Powers, their conversation delves into how Sadri has changed patient care and management, the advancements he’s most excited for, and his thoughts on those who have yet to adopt interventional glaucoma as a practice mainstay. 

In this episode, learn about:  

• The burden of drops on practices 
• The characteristics to look for when choosing a minimally invasive procedure 
• Metrics to evaluate success for interventional glaucoma procedures 
• How patient education has evolved 
• How interventional glaucoma procedures contribute positively toward patient adherence and engagement 

RESOURCES:  

Carey Powers: https://ois.net/carey-powers/     

Dr. Ehsan Sadri: https://ois.net/ehsan-sadri-md/ 

Peter Michael Benz, Ph.D., joins The Rob & Jai Show, an edition of the OIS podcast, to discuss Boehringer Ingelheim International GmbH’s ambitious goals for the ophthalmology field, particularly on glaucoma, and the reasons behind the company’s partnership with Ravana Therapeutics, as well as offer advice on what makes for a good partnership. 

In this episode of the OIS podcast, learn about:  

• Boehringer emerging from stealth mode for eye health projects  
• Their plans for their investments in the U.S. 
• Why it was so important for Boehringer to partner up with Ravana 
• What makes a good partnership 

RESOURCES:  
Dr. Rob Rothman: https://ois.net/robert-rothman-md/ 
Dr. Jai Parekh: https://ois.net/jai-g-parekh-md-mba/ 
Dr. Peter Michael Benz: https://ois.net/peter-michael-benz-phd/  
 

Malvina Eydelman, M.D., CEO of The Collaborative Community on Ophthalmic Innovation (CCOI), joins The Rob & Jai Show, an edition of the OIS podcast, to discuss what innovation in the industry looks like in the next 30 years—and if we’re hitting a saturation mark. Plus, a deep dive into Eydelman’s career in the FDA, her current role at the CCOI, and a big announcement of her next initiative. 

In this episode of the OIS podcast, learn about:  

• Eydelman’s time at the FDA and the many hats she wore 
• The goal and plans of the CCOI 
• The role of AI in digital management and getting more patients into the system 
• Details about Eydelman’s next big initiative 

RESOURCES:  

Dr. Rob Rothman: https://ois.net/robert-rothman-md/ 
Dr. Jai Parekh: https://ois.net/jai-g-parekh-md-mba/  

Dr. Malvina Eydelman: https://ois.net/malvina-eydelman/  

Adrienne Graves, Ph.D. returns, this time on The Rob & Jai Show, an edition of the OIS podcast. As a trailblazer of the industry, Dr. Graves shares her insights and lessons learned as a CEO and board member of several companies. She also discusses getting treatment to areas around the world that need it the most, how AI will affect and continue to impact eyecare and healthcare at large, and utilizing ophthalmic data for systemic disease diagnosis and management. 

In this episode of the OIS podcast, learn about:  

• Getting affordable and accessible ophthalmological therapies across the world 
• The differences between being a CEO and a board member 
• The impact of AI on eyecare and how it applies to practices 
• The next hot topic of ophthalmology 

RESOURCES:  

Dr. Rob Rothman: https://ois.net/robert-rothman-md/ 
Dr. Jai Parekh: https://ois.net/jai-g-parekh-md-mba/  

Adrienne Graves, Ph.D.: https://www.linkedin.com/in/adriennegraves  

Theresa Heah, M.D., MBA, co-founder, vice-chair, and CEO of Eyexora, speaks with host Carey Powers at this year’s Ophthalmology Innovation Summit about her company’s fresh approach to building an ophthalmology company that centralizes R&D, clinical, regulatory, and commercial expertise into a “one-stop shop.” Heah delves into the advantages of the hub and spoke model and how it will help overcome the gaps in the eye care landscape, as well as their plans to expand to the UK. 

In this episode of the OIS podcast, learn about:  

· Eyexora’s mission as a unique hub and spoke company dedicated to accelerating clinical innovation 

·  The barriers in the ophthalmology field and how Eyexora’s approach will help overcome them 

·  The advantages of building relationships on a global scale 

·  Milestones and scientific areas to look out for in 2026 

RESOURCES:  

Carey Powers: https://ois.net/carey-powers/  

Theresa Heah: https://www.linkedin.com/in/theresaheah  

Eyexora: https://eyexora.com/ 

Grace Ambrose-Zaken, Ph.D., president and CEO of Safe Toddles, speaks with host Robert Rothman about her mission to create a safer, easier-to-navigate world for children—perhaps one of the most underserved patients in eye care. Dr. Ambrose-Zaken discusses her breakthrough invention, the Pediatric Belt Cane, and how it transformed early mobility for blind children. 

In this episode of the OIS podcast, learn about:  

• Why we need to have empathy and understanding for the visually impaired, especially children 
• The advantages of the belt cane over the white cane 
• The impediments of getting the belt cane to patients 
• How to support the visually impaired and Safe Toddles’ mission 

What are the key qualities to being effective teammates? David Esposito, President and CEO of ONL Therapeutics, and Connie Chang, Chief Operating Officer of ONL Therapeutics, chat with host James Murray on the importance and value of transparency, trustworthiness, vulnerability, and candor amongst leadership to establish a strong company foundation.
In this episode of the OIS podcast, learn about:

• Handling the little problems before they become big problems
• The ability to execute big ideas effectively and efficiently
• Building trust between companies, investors, and all other parties
• Navigating the challenges of scaling

At this year’s Retina Innovation Summit, industry experts and leaders gathered in a two-part discussion on investment trends, regulatory environment and FDA changes, emerging therapies in ophthalmology, and more. Panelists include: Laura Feinleib, Managing Director at Redmile Group; Derrick Li, Chief Strategy Officer at ODC Life Sciences; Cameron Taylor, Managing Director at BofA Securities | Life Sciences; Wayne Caulder, Vice President & General Manager of Surgical (U.S. & Canada) at Bausch + Lomb; Paul Hallen, Vice President & Distinguished Fellow at Alcon; Nida Sen, MD, VP, Ophthalmology Strategy & Development Head at Sanofi; and Julian Smith, General Manager Portfolio Commercial Strategy - Eye Care at AbbVie.

In this panel learn about:
🔹Investment trends in public and private markets
🔹Regenerative therapies, such as gene therapy and cell therapy
🔹The impact of patient and therapy adoption challenges—and how to navigate them
🔹Advice for entrepreneurs and start-ups on the best key strategies on driving partnership interest and networking

Join Dr. Robert Rothman as he talks with Rajan Shukla about his journey from a family legacy in ophthalmology to pioneering new treatments for anterior segment diseases. Rajan shares how Vital Tears is making serum tears accessible nationwide and how Bright Star Therapeutics is developing innovative therapies like BrightMEM™ to transform ocular surface care.
In this episode, learn about:

• The story behind Vital Tears and Bright Star Therapeutics
• BrightMEM™ and its impact on treating limbal stem cell deficiency
• The future of ocular surface and retinal therapies

Hear how innovation is shaping the future of eye care.

This week on The Rob & Jai Show, an edition of the OIS Podcast, Dr. Rob Rothman and Dr. Jai Parekh welcome Tomas Navratil, PhD, Chief Development Officer at Glaukos, to discuss the company’s remarkable transformation from MIGS pioneer to a diversified global leader in ophthalmology. Glaukos is advancing a robust pipeline that spans devices, pharmaceuticals, and drug-device combinations—reshaping the future of eye care.

Highlights from the episode include:

• How Glaukos tripled its R&D pipeline over the past decade
• A shift from 100% device focus to 70% pharma or drug-device innovation
• Next-gen iDose TR with double the payload heading into clinical development
• Positive Phase 3 results for Epioxa, a non-surgical therapy for keratoconus

Tune in now to hear how Glaukos is stepping into its next chapter as a true ophthalmic powerhouse.